Axplora Announces €35 Million Expansion at Farmabios
Axplora to expand its Farmabios site in Gropello Cairoli, Italy, with a €35 million investment.
Axplora
10.03.2025 • News
Axplora Expands Capabilities at Le Mans Site
Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
10.10.2023 • News
Axplora’s Farmabios Gets cGMP Approval for New Production Unit in Italy
Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for the first line of its new production unit at Gropello Cairoli, Italy, expanding its large scale manufacturing capabilities for high potent active pharmaceutical ingredients (HPAPIs) and steroids.
22.02.2023 • Topics • Innovation
Axplora Aims to Make Pharmaceutical Supply Chains More Stable
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
07.12.2022 • News
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
28.11.2022 • News
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
